Epigenica published an application note demonstrating how EpiFinder™ GenomePro quantitatively profiles multiple histone modifications and DNA methylation in K562 cells treated with Vorinostat.
Published
Signal category
Research & Knowledge
Quote
“In our application note, we use K562 cells treated with increasing concentrations of Vorinostat to demonstrate how EpiFinder™ GenomePro quantitatively profiles multiple histone modifications alongside DNA methylation in the same study.”
— Epigenica team
Company
Epigenica
Epigenomics Switched On. Multiplexed Insight, Translational Impact
- Industry
- Biotechnology
- Location
- Solna, SE
- Company size
- 21 employees
Epigenica is a life sciences technology company at the forefront of innovations in epigenetic research. The company’s EpiFinder platform enables researchers to perform comprehensive epigenetic studies at unprecedented speed, scalability, and affordability. Epigenica is building a portfolio of products based on the EpiFinder platform to offer comprehensive high-throughput profiling at different depths of detail with an array of possible starting materials. The platform is powered by the company’s patented and proprietary high-throughput, multiplex, quantitative ChIP-seq technology (hmqChIP), the first commercial kit of its kind. With the advantages of the EpiFinder platform, Epigenica is helping researchers advance biomedical research, drug discovery and development, precision medicine, diagnostics, and therapeutics for aging and longevity.
Founded 2020